Table 1.
Patients’ characteristics among the whole population.
| Characteristics | Class | All | BRCA Mutation | BRCA Wild-Type | Not Screened | p |
|---|---|---|---|---|---|---|
| n = 1199 (100%) | n = 46 (3.8%) | n = 221 (18.4%) | n = 932 (77.7%) | |||
| Age (mean) | 48.6 | 39.5 | 41.7 | 50.6 | <0.01 | |
| Menopausal Status | pre | 747 (62.8) | 41 (89.1%) | 187 (85.0%) | 519 (56.2%) | <0.01 |
| post | 442 (37.2) | 5 (10.9%) | 33 (15.0%) | 404 (43.8%) | ||
| BMI (mean) | 24.7 | 22.8 | 23.6 | 25.1 | <0.01 | |
| BMI class | (15,19] | 72 (6.0) | 6 (13.3) | 17 (7.7) | 49 (5.3) | <0.01 |
| (19,25] | 664 (55.7) | 31 (68.9) | 147 (66.5) | 486 (52.4) | ||
| (25,30] | 299 (25.1) | 4 (8.9) | 43 (19.5) | 252 (27.2) | ||
| (30,50] | 158 (13.2) | 4 (8.9) | 14 (6.3) | 140 (15.1) | ||
| Family history of BC | no | 887 (74.2) | 12 (26.1%) | 104 (47.7%) | 771 (82.7%) | <0.01 |
| yes | 309 (25.8) | 34 (73.9%) | 114 (52.3%) | 161 (17.3%) | ||
| Clinical tumor size | T1 | 70 (5.8%) | 5 (10.9%) | 22 (10.0%) | 43 (4.6%) | <0.01 |
| T2 | 798 (66.6%) | 28 (60.9%) | 153 (69.2%) | 617 (66.3%) | ||
| T3 | 330 (27.5%) | 13 (28.3%) | 46 (20.8%) | 271 (29.1%) | ||
| Clinical | N0 | 525 (43.8%) | 17 (37.0%) | 93 (42.1%) | 415 (44.6%) | 0.51 |
| nodal status | N1-N2-N3 | 673 (56.2%) | 29 (63.1%) | 128 (57.9%) | 516 (55.4%) | |
| Histology | NST | 1062 (90%) | 43 (93.5%) | 213 (96.4%) | 806 (88.3%) | 0.03 |
| others | 118 (10%) | 3 (6.5%) | 8 (3.6%) | 108 (11.6%) | ||
| Grade | I-II | 479 (41.4%) | 10 (23.3%) | 76 (34.7%) | 393 (43.9%) | 0.01 |
| III | 678 (58.6%) | 33 (76.7%) | 143 (65.3%) | 502 (56.1%) | ||
| Mitotic Index (mean) | 25.1 | 30.8 | 25.6 | 24.6 | 0.25 | |
| Subtype | luminal | 528 (44.0%) | 15 (32.6%) | 75 (33.9%) | 438 (47.0%) | <0.01 |
| TNBC | 376 (31.4%) | 27 (58.7%) | 83 (37.6%) | 266 (28.5%) | ||
| HER2 | 295 (24.6%) | 4 (8.7%) | 63 (28.5%) | 228 (24.5%) | ||
| str TILs (mean) | 20.0 [10.0–30.0] | 20.0 [13.8–40.0] | 20.0 [10.0–40.0] | 15.0 [10.0–30.0] | 0.02 | |
| IT TILs (mean) | 5.0 [5.0–15.0] | 5.0 [5.0–11.2] | 7.5 [5.0–20.0] | 5.0 [3.0–15.0] | 0,47 | |
| NAC Regimen | AC | 235 (19.6%) | 4 (8.7%) | 25 (11.4%) | 206 (22.2%) | <0.01 |
| AC-Taxanes | 845 (70.7%) | 41 (89.1%) | 180 (81.8%) | 624 (67.1%) | ||
| Taxanes | 25 (2.1%) | 1 (2.2%) | 6 (2.7%) | 18 (1.9%) | ||
| Others | 91 (7.6%) | 0 (0.0%) | 9 (4.1%) | 82 (8.8%) | ||
| pCR class | No pCR | 911 (76.2) | 25 (54.3) | 157 (71.4) | 729 (78.4) | <0.001 |
| pCR | 285 (23.8) | 21 (45.7) | 63 (28.6) | 201 (21.6) | ||
| Nodal involvment | 0 | 682 (57.0) | 35 (76.1) | 141 (64.1) | 506 (54.4) | 0.003 |
| 1–3 | 341 (28.5) | 6 (13.0) | 58 (26.4) | 277 (29.8) | ||
| ≥4 | 174 (14.5) | 5 (10.9) | 21 (9.5) | 148 (15.9) | ||
| str TILs (mean) | 10.0 [5.0–15.0] | 15.0 [5.0–20.0] | 10.0 [5.0–15.0] | 10.0 [5.0–15.0] | 0.36 | |
| IT TILs (mean) | 5.0 [2.0–10.0] | 5.0 [4.3–10.0] | 5.0 [2.0–10.0] | 5.0 [2.0–10.0] | 0.57 |
Missing data: Menopausal status, n = 10; BMI (continuous), n = 6; BMI class, n = 6; Family history, n = 3; Clinical tumor stage, n = 1; Clinical nodal status, n = 1; Histology, n = 19; Grade, n = 42; Mitotic index, n = 502; Pre-NAC str TILs, n = 482; Pre-NAC IT TILs, n = 482; NAC regimen, n = 3; pCR status, n = 3; Post-NAC Nodal involvment, n = 2; Post-NAC str TILs, n = 482; Post-NAC IT TILS, n = 714. Abbreviations: NAC = neoadjuvant chemotherapy; BMI = body mass index; NST = no special type; TNBC = triple negative breast cancer; str TILs = stromal tumor-infiltrating lymphocytes; IT TILs = intratumoral-infiltrating lymphocytes; AC = anthracyclines; pCR = Pathologic complete response. The “n” denotes the number of patients. In case of categorical variables, percentages are expressed between brackets. In case of continuous variables, mean value is reported. In case of nonnormal continuous variables, median value is reported, with interquartile range between brackets.